首页> 美国卫生研究院文献>Iranian Journal of Pharmaceutical Research : IJPR >The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Process and Inflammatory Biomarkers in Patients Following Percutaneous Coronary Intervention (PCI)
【2h】

The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Process and Inflammatory Biomarkers in Patients Following Percutaneous Coronary Intervention (PCI)

机译:经皮冠状动脉干预后患者静脉注重对血糖再灌注过程和炎症生物标志物的潜在影响(PCI)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study aimed to investigate the efficacy of calcitriol on Ischemia-reperfusion Injury (IRI) and inflammatory biomarkers in patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) undergoing elective Percutaneous Coronary Intervention (PCI). A total of 72 patients with NSTEACS were randomly divided into two groups: (1) the calcitriol-treated group, treated with three mcg intravenous calcitriol administered before PCI (n = 36) and (2) the control-treated group (n = 36) The serum high-sensitivity C-reactive protein (hs-CRP), high-sensitivity interleukin-6 (hs-IL-6), creatinine kinase (CK)-MB and cardiac troponin I (cTnI) levels were measured before PCI and 24 h after PCI in both groups. The patients were followed up for the detection of the prevalence of major adverse cardiac events (MACE) in 180 days after PCI in both groups. Compared to pre-PCI, the serum hs-CRP, hs-IL-6, CK-MB, and cTnI levels were increased at 24 h after PCI (all < 0.05) in both groups. However, change in the levels of hs-CRP and hs-IL-6 were significant ( = 0.04 and = 0.02, respectively). Changes in the levels of CK-MB and cTnI were non-significant ( = 0.15 and = 0.39, respectively). No MACE (death, Q wave MI, target vessel revascularization, ischemic stroke) was detected in any patient in any group during a 3-month follow-up. Administration of calcitriol in patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum inflammatory biomarkers in the serum (hs-CRP and hs-IL-6) and thus decrease the inflammatory reaction caused by PCI.
机译:本研究旨在探讨钙咪唑对患有选修经皮冠状动脉干预(PCI)的非ST段抬高急性冠状动脉综合征(NSTEACS)的缺血再灌注损伤(IRI)和炎性生物标志物的疗效。将72名NSTEACs患者随机分为两组:(1)钙质处理组,用三种MCG静脉注重钙二醇处理,在PCI(n = 36)和(2)对照处理组(n = 36)之前(n = 36 )在PCI和PCI之前测量血清高灵敏度C-反应蛋白(HS-CRP),高敏感性白细胞介素-6(HS-IL-6),肌酐激酶-MB和心肌肌钙蛋白I(CTNI)水平两组PCI后24小时。患者在两组PCI后180天内检测主要不良心脏事件(MACE)的患病率。与PCI预筛选,血清HS-CRP,HS-CRP,HS-IL-6,CK-MB和CTNI水平在两组中(全部<0.05)后24小时增加。然而,HS-CRP和HS-IL-6水平的变化显着(分别= 0.04且= 0.02)。 CK-MB和CTNI水平的变化分别是非显着的(= 0.15且= 0.39)。在3个月随访期间,在任何患者中,在任何患者中检测到任何MACE(死亡,Q Wave MI,靶血管血运血症)在任何患者中检测到任何患者。在患有选修PCI的非ST段升高急性冠状动脉综合征患者中施用钙质可以衰减血清中血清炎症生物标志物的增加(HS-CRP和HS-IL-6),从而降低PCI引起的炎症反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号